期刊
JOURNAL OF HEPATOLOGY
卷 62, 期 5, 页码 1187-1195出版社
ELSEVIER
DOI: 10.1016/j.jhep.2015.02.010
关键词
TACE; HCC; Patient selection; Response; mRECIST; Overall survival; Hepatocellular carcinoma; Intermediate stage
资金
- Bayer Schering Pharma
- Lilly Pharma
- Boehringer Ingelheim
Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma (BCLC B). Further improvement of the use of TACE was the subject of intense clinical research over the past years. The introduction of DEB-TACE brought more technical standardization and reduction of TACE related toxicity. The use of dynamic radiologic response evaluation criteria (EASL, mRECIST), uncovered the prognostic significance of objective tumor response. Finally, new approaches for better patient selection for initial and subsequent TACE treatment schedules will limit the use of TACE to some extent but have the potential to improve outcome for patients at risk for TACE-induced harm. (C) 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据